Business
ORYZON to Host Virtual KOL Event on July 9, 2025
To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat’s Phase III PORTICO-2 trial in BPDMADRID and CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it will host a virtual KOL event on Wednesday, July 9, 2025 at 12:00 pm ET. The event, moderated by Michael Ropacki, PhD and Oryzon’s CMO for
About this update from Oryzon Genomics Sa
[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"text","content":"To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat’s Phase III PORTICO-2 trial in BPD","length":139,"tagName":"p"},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it will host a virtual KOL event on Wednesday, July 9, 2025 at 12:00 pm ET. The event, moderated by Michael Ropacki, PhD and Oryzon’s CMO for CNS, will feature insights from leading experts:","length":409,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Alan F. Schatzberg, MD, MS(Hon) - Stanford University School of Medicine","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Emil F. Coccaro, MD - The Ohio State University College of Medicine","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Eric Hollander, MD - Albert Einstein College of Medicine","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"Sarah Fineberg, MD, PhD - Yale University School of Medicine","length":60,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":255,"olType":false},{"type":"text","content":"The event will provide an overview of the current social and clinical challenges for patients with Borderline Personality Disorder (BPD). It will highlight the absence of approved pharmacological treatments, the limitations of off-label medications, and the critical role of agitation and aggression in BPD and other psychiatric conditions. The discussion will also explore the potential of emerging therapies, with a focus on vafidemstat. The panel will also briefly review Oryzon’s recent interactions with the FDA and the design of vafidemstat’s PORTICO-2 Phase III trial...